Board of Directors

Luke Evnin, PhD - Potenza Chairman, and Co-Founder and Managing Director of MPM Capital

Prior to co-founding MPM in 1997, Luke Evnin was employed by the venture capital firm Accel Partners. He received his PhD in Biochemistry from the University of California – San Francisco. He has devoted significant efforts since 2000 to working with the Scleroderma Research Foundation, serving as Chairman since 2002. Dr. Evnin also devotes energy to the External Advisory Board at the Lewis-Sigler Institute for Quantitative Genomics at Princeton, the External Advisory Boards for QB3, the Mission Bay Capital Fund at UCSF, and the Boston University Scleroderma CORT. View Profile

Daniel J. Hicklin, PhD - Potenza President and CEO

Daniel Hicklin brings to Potenza over 25 years of biopharmaceutical research and operations experience with particular expertise in oncology drug development. Dr. Hicklin co-founded Potenza in 2014 and is the company’s President and CEO. He has served as a Managing Director at the life sciences venture capital investment firm MPM Capital since 2014 and is also a board member of Tizona Therapeutics and Harpoon Therapeutics.  Previously, Dr. Hicklin served as President and Chief Scientific Officer of CoStim Pharmaceuticals, which was acquired by Novartis in 2014. From 2007 to 2013, he held several positions at Merck Research Laboratories and the former Schering-Plough Research Institute, most recently leading Biologics Strategy for Oncology and overseeing immuno-oncology discovery research at Merck Research Laboratories in Boston.  Dr. Hicklin began his career at ImClone Systems where he held several positions of increasing responsibility from 1987 - 2007, most recently serving as Vice President of Experimental Therapeutics. Dr. Hicklin’s team at ImClone supported the development and FDA approval of the cancer treatment ERBITUX® (Cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), necitumumab, and other cancer therapies that were acquired by Eli Lilly in 2008. Dr. Hicklin has co-authored over 200 peer-reviewed publications and is an inventor on numerous issued and pending patents. Dr. Hicklin received his Master’s and PhD in Microbiology & Immunology from New York Medical College and earned his BS from the University of Iowa. View Profile

Arnold Oronsky, PhD - General Partner of InterWest Partners

In addition to his responsibilities at InterWest, Arnold Oronsky also serves as a senior lecturer at the Department of Medicine at Johns Hopkins Medical School. Prior to joining InterWest’s healthcare investing team full-time in 1994, Dr. Oronsky was Vice President for Discovery Research of the Lederle Laboratories division of American Cyanamid Company where he directed the research for new drugs. Dr. Oronsky received a PhD in immunology from Columbia University and has published more than 125 articles in scientific journals. View Profile

Shunichiro Matsumoto, PhD - Vice President of Astellas Innovation Management (AIM)

Dr. Shunichiro Matsumoto is currently Vice President of Innovation Management at Astellas Pharma Inc., based in Tokyo, Japan, and also President of Astellas Venture Management LLC, located in Menlo Park, CA, USA. Prior to the establishment of Innovation Management in October 2013, he served as Senior Director of Product and Portfolio Strategy at Astellas Pharma Inc. He has a 5-year experience including serving as Investment Director in the venture capital business at Astellas Venture Management LLC and 14 years of experience in R&D specializing molecular biology at Astellas Pharma Inc. and the former Yamanouchi Pharmaceutical Co., Ltd.     Dr. Matsumoto received his PhD in Medicine from University of Tsukuba, an MSc in Agriculture from Kyoto University, and an MBA from McGill University.